Main Conference Day 1 (28th April 2026) - CET/CEST (Cent Europe Summer, GMT+2)
- Michael Butler - Principal Investigator, Cell Technology, NIBRT
- Lasse Ebdrup Pedersen - Associate Professor, The Technical University of Denmark
- Jesús Lavado-García - Co-PI and Group Leader of the Mammalian Cell and Bioprocess Engineering Group, DTU Biosustain
- Dénes Zalai - Director Technology, Eleva Biologics
- Michael Palige, PhD - Drug Substance CMC Lead - Biotherapeutics Process Development Europe, Takeda Pharmaceutical Company Limited
- Ulrich Rümenapp - Senior Biotech Program Lead, Bayer AG
- Margit Holzer - Scientific Director, Ulysse Consult
- Alois Jungbauer - Professor, Dept. of Biotechnology, BOKU University
- Hubert Mayerhofer - Senior Manager DSP Development, Novartis
- Felix Wittkopp - Director of Purification Development Gene Therapy - Gene Therapy Technical Research & Development, Roche, Germany
- Binod Prasad - Senior Principal Scientist, Abalos Therapeutics GmbH
- Jordan Turnbull - Co-Founder, Co-CEO, CSO, Fuse Vectors
- Thibaut Angevin - Director CMC Proteins, BioNTech SE
- Francisca Gouveia - Innovation Data & Digital Lead, Novartis, France
- Steffen Goletz, PhD - Full Professor, Head of Biotherapeutic Glycoengineering and Immunology - Institute for Biotechnology & Biomedicine, Danish Technical University
Have a Solution for This Challenge?
This session is your platform to demonstrate leadership and technical expertise. Present your data, case studies, and innovative solutions to a targeted audience of senior scientists and engineers looking to solve hurdles in their production processes.
To learn more about sponsoring this session, contact us at Partners@informaconnectls.com
- Lovro Kramer - Senior Principal Scientist, Cell Line Screening and Development - Biologics Research Center, Novartis Biomedical Research
- Bjørn Voldborg - Director CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability
- Ali Saleemi - Associate Director, Bayer
- An increasing number of molecules is coming through the pipeline because of AI for drug discovery and clinical trials, requiring process development and operations to become more cost and time effective.
- With the rise of AI, the expectation is for digital tools to streamline process development while delivering robust, high performance processes.
- Examples of data management and process modeling applications will be shown, which indicate that wet-lab experimentation can be reduced, when used alongside the traditional way of working.
- Moritz von Stosch - Co Founding Partner, HINA Bioventures
- Sabrina Simpson-Koch - Senior Scientist - Gene Therapy Technical Research & Development, Roche
EVs are rapidly growing, but with no established purification platform
Current state-of-the-art purification strategies
Pros and Cons of differing approaches:
Centrifugation
Filtration
Chromatography
The future of EV purification: what will a platform look like?
- Bernd Giebel - Professor for Translational EV research, University Hospital Essen of the University of Duisburg-Essen
- Patricia Pereira Aguilar - Senior Scientist – Institute of Bioprocess Science and Engineering, BOKU
- Jack Cordrey - Senior Bioprocessing Specialist, Thermo Fisher Scientific
- Christopher Fox - Senior Technical Project Leader, Process Development, FUJIFILM Diosynth Biotechnologies
- Hollie Bartley - Director, Process Development, Resolution Therapeutics
- Pablo Mancheño Corvo - Associate Scientific Director, Takeda, Spain
- Peter Satzer - Founder & CTO, print4biotech (p4b)
This presentation explores how Artificial Intelligence and Machine Learning contribute differently to modern bioprocess optimization. Five industrially relevant showcases will be discussed - spanning upstream and downstream processes, from monoclonal antibodies to viral vectors, and from small-scale development to manufacturing scale. Emphasis will be placed on the digital transformation journey from manual development work toward fully autonomous biomanufacturing, highlighting solution paths that enable faster, more consistent, and intelligent process optimization across the product lifecycle.
- Mark Duerkop - Chief Executive Officer, Novasign, Austria
Explore a showcase of scientific excellence. Discover the latest data and technical breakthroughs in our dedicated Poster Hall in the Exhibit Hall. Engage directly with the authors to discuss their findings, methodology, and results during this focused networking break.
1st stop on the Sartorius booth: Experience a brief, guided tour of an intensified upstream suite within Sartorius’ Mixed Reality Application. See how technologies interact as a process is executed and gain a unique perspective on how Sartorius solutions work together both within a suite and across the broader manufacturing process.
2nd stop on the Sartorius booth: Experience process intensification in a tangible way at our booth with the Smart PI Counter. This interactive desk features ten RFID-enabled glass cubes—each representing a key aspect of Sartorius solutions for intensified bioprocessing. Simply place a cube on the central spot and the screen instantly reveals targeted content, from application notes to high-level process overviews.
Guided by a Sartorius expert, you can explore concrete use cases, discuss practical implementation steps, and see how process intensification could look in your own environment. The Smart PI Counter turns complex options into clear, structured insights.
- Miriam Monge - Head of Customer and Industry Advocacy Strategy, Sartorius
- Harry Starkey - Research Manager, Informa Connect
- Chris Spivey - Director of Industrial Relations and Strategic Partnerships, Informa Connect
The latest state of play on the European Biotech Act to be proposed by the European Commission at the end of 2025, and its impact for the biotech industry.
- Vittoria Carraro - Policy Officer, European Commission
- Daniela Ottini - SVP, Manufacturing and Supply Head of Specialty Care, Sanofi
- Andrea Johnston, PhD - Senior Director, BioPhorum
- William Doyle - Business Technology Partner, MSD, Ireland
Head to the Start-Up Zone for Cocktails and Innovation! Uncover the latest developments from industry trailblazers:
- 17:15 - p4b GmbH
- 17:25 - Novasign
- 17:35 - nagene GmbH
- 17:45 - bespark*bio
- 17:55 - SimVantage
- 18:05 - Qubicon
- 18:15 - Onyx Biotech
- 18:25 - IamFluidics BV
- 18:35 - LABMaiTE GmbH
- Matthias Müllner - CEO, bespark*bio
- Natascha Missbach - CEO & Co-Founder, nagene GmbH
- Jonas Bermeitinger - CEO, LABMaiTE GmbH